Vaccines against SARS-CoV-2 have been rapidly approved. Although pivotal studies were
conducted in healthy volunteers, little information is available on the safety and efficacy of …

Background Hematopoietic stem cell transplant (HSCT) recipients are at increased risk of
mortality and morbidity with coronavirus disease 2019 (COVID‐19) due to severe immune …

While several studies have described the clinical course of patients with coronavirus
disease 2019 (COVID-19), direct comparisons with patients with seasonal influenza are …

Lymphoma represents a heterogeneous hematological malignancy (HM), which is
characterized by severe immunosuppression. Patients diagnosed of coronavirus disease …

Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-
19), but the mechanisms underlying virus–host interactions during cancer therapies remain …

Background The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation
(HSCT) recipients is almost uniformely considered poor. The aim of present study was to …

Outcome of early treatment of COVID‐19 with antivirals or anti‐spike monoclonal antibodies
(MABs) in patients with haematological malignancies (HM) is unknown. A retrospective …

Following the spread of the SARS-CoV-2 infection and coronavirus disease 2019 (COVID-
19) to a global pandemic, concerns have arisen for the disease impact in at-risk populations …

COI notes: K. Mihara: Research funding; TAKARA BIO. Lecture fee; Janssen
Pharmaceutical, Sanofi, and CSL Behring. YA: Honoraria; Celgene, Takeda Pharmaceutical …

The ability of patients with hematologic malignancies (HM) to develop an effective humoral
immune response after COVID-19 is unknown. A prospective study was performed to …